General Characteristics
Age: 72 years
Gender: Female
Disease Origin: Sacral
Disease Status: Recurrent
Prior Radiation: No
Prior Systemic Therapy: No
Source: Silke Bruderlein, Peter Moller; University of Ulm
Molecular Features
Cell Morphology: Physaliferous
TBXT Expression: Positive; with T amplification
TBXT Localization: Nuclear
CD24 Expression: Positive
HLA Type: A11 (View Histocompatibility Report)
Sequence Data: WGS, Exome and Transcriptome data available: raw sequencing data in Cavatica (Chordoma Foundation Dataset) and summary data in PedcBioportal. Contact researchteam@chordoma.org with any questions.
SMARCB1 Status: Wild-type
Validation Results: Validation Report
Growth Conditions
Growth Medium: (4:1) IMDM/RPMI 1640 + 10% FBS + 1% NEAA + 1% GlutaMAX
Freeze Medium: 70% complete growth medium supplemented with an additional 20% fetal bovine serum and 10% DMSO
Culture Conditions: Temperature: 37°C
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Subculturing Instructions: Cell Culture Procedures
Publications
Characterized By:
- Brüderlein S, Sommer J, Meltzer P, Li S, Osada T et al. (2010) Molecular Characterization of Putative Chordoma Cell Lines. Sarcoma: 630129. PubMed: 21253487.
Additional References:
- Scheil-Bertram S, Kappler R, von Baer A, Hartwig E, Sarkar M et al. Molecular profiling of chordoma. Int J Oncol 44(4):1041-55. PubMed: 24452533.
- Xia M, Huang R, Sakamuru S, Alcorta D, Cho MH et al. (2013) Identification of repurposed small molecule drugs for chordoma therapy. Cancer Biol Ther 14(7):638-47. PubMed: 23792643.